21 May 2020Midatech Pharma PLC("Midatech" or the "Company")Midatech Pharma PLC Announces Closing of US$3.0 Million Registered Direct Offering Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on delivering innovative oncology and...
General Releases
US$3.0 Million Registered Direct Offering
Midatech Pharma PLC("Midatech" or the "Company")Midatech Pharma PLC Announces US$3.0 Million Registered Direct Offering 18 May 2020 - Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on delivering innovativeoncology and rare...
UK Placing to Raise £1.8 million
18 May 2020NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THEUNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION INWHICH OFFERS OR SALES WOULD BE PROHIBITED BY...
Midatech’s MTX110 Receives Orphan Designation for DIPG
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce that the U.S. Food and Drug Administration ("FDA") has granted the Company orphan...
Headline Results of MTX110 Phase I DIPG Study
Phase II Dose Confirmed and Encouraging Survival Data Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio‐deliveryand biodistribution of medicines, is pleased to announce encouraging headline results from a...